Pfizer has filed two lawsuits against the metabolic-focused startup Metsera and Novo Nordisk as of Tuesday. The first suit, filed last Friday, claims that Novo Nordisk’s rival bid for Metsera is a move “to suppress competition,” Pfizer said in a press release. Metsera could be a vital acquisition for either company. The company is developing…
2025 pharma M&A surges to $70 billion in major deals
Novo Nordisk’s $5.2 billion acquisition of Akero Therapeutics sits at the center of 2025’s hottest M&A space: MASH/metabolic disease. The deal, announced October 9, represents the largest of three major Fibroblast Growth Factor 21 (FGF21) analog acquisitions in five months. Across the broader landscape, 2025 pharma M&A activity reached approximately $70 billion in upfront consideration…